News Contact Us

Roche’s Tecentriq bags priority review for treating advanced NSCLC

Author : Pankaj Singh | Published Date : 2020-02-20 

Swiss multinational pharmaceutical company, Roche has recently revealed that the U.S. FDA has acknowledged its sBLA (supplemental Biologics License Application) and approved Priority Review for Tecentriq® (atezolizumab) as an initial monotherapy for patients suffering from advanced NSCLC (non-squamous and squamous non-small cell lung cancer) without ALK mutations with elevated PD-L1 expression or EGFR. Reportedly, the FDA is anticipated to come to a decision by June 19, 2020.

According to reliable sources, this sBLA is centered around the findings from the Phase III IMpower110 trial, which demonstrated that Tecentriq monotherapy enhanced OS (overall survival) by 7.1 months when equated to chemotherapy in patients with extreme PD-L1 expression. Tecentriq’s safety profile seemed to be coherent with its known safety profile, with no additional safety signals being detected.

Speaking on the move, Levi Garraway, M.D., Ph.D., Head of Global Product Development and Chief Medical Officer, Roche, said that revisiting the IMpower110 trial, Tecentriq solely established a noteworthy improvement in OS when compared to chemotherapy for newly diagnosed NSCLC patients.

Additionally, the company is closely working with the FDA to release its chemotherapy-free alternative for all NSCLC patients as soon as possible.

Prior to this news, Roche had made headlines when the China National Medical Products Administration (NMPA) granted approval Tecentriq®, in association with chemotherapy ( etoposide and carboplatin), for the initial therapy of patients with ES-SCLC (extensive-stage small cell lung cancer).

Commenting on which, Garraway added that small cell lung cancer is a crucial segment with huge unmet needs in China. Besides, there haven’t been any major advances in this sector until now.

With this consent, Tecentriq would become the first-ever cancer immunotherapy to be accessible in China for the first-line therapy of ES-SCLC. This would come as an important and swift leap for patients, in terms of medical progression, who suffer from this chronic disease.

Source Credit: http://www.globenewswire.com/news-release/2020/02/19/1986747/0/en/FDA-grants-priority-review-to-Roche-s-Tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Chipmaker TSMC mulls over Germany for first Europe chip plant

Published Date: 2021-07-27         Author: Pankaj Singh

Taiwan Semiconductor Manufacturing Co Ltd (TSMC) stated that it is too early to talk about its factory expansion in Germany and that the talks are in the initial phases as the European Union seeks to reduce chip imports amid the supply shortage. The European Commission had conducted discussions w... Read More

COVID-19 cases surge in Australia, police warn of protest repeat

Published Date: 2021-07-26         Author: Pankaj Singh

Despite a weeks-long stay-at-home order, Australias most populated state reportedly recorded an increase in new COVID-19 cases, and police swore to suppress any recurrence of the raucous anti-lockdown rally over the weekend. New South Wales, which had imposed a lockdown in Sydney to curb the wide... Read More

LG commits to sustainability mission, aims to go 100% renewable by 2050

Published Date: 2021-07-23         Author: Pankaj Singh

South Korean multinational electronics firm LG Electronics Inc. recently announced its plans to transition to 100% renewable energy by 2050 as part of its sustainability strategy. For the record, the firm had earlier committed to carbon neutrality via the Zero Carbon 2030 initiative, which aims t... Read More

© 2021 Fractovia. All Rights Reserved